Michael Rafaelof, None;
Andrew Moshfeghi, Alimera, Inc. (C), Alimera, Inc. (R), Allergan, Inc. (C), Clearside Biomedical, Inc (C), Clearside Biomedical, Inc (S), Clearside Biomedical, Inc (R), EyePoint Pharmaceuticals (C), EyePoint Pharmaceuticals (S), EyePoint Pharmaceuticals (R), Genentech, Inc. (C), Genentech, Inc. (F), Genentech, Inc. (S), Graybug Vision Inc. (C), Graybug Vision Inc. (S), Graybug Vision Inc. (R), Novartis - Ophthalmology (C), Novartis - Ophthalmology (S), Novartis - Ophthalmology (R), Novartis - Ophthalmology (F), OptiSTENT, Inc. (I), Pr3vent, Inc (I), Regeneron, Inc. (C), Regeneron, Inc. (S), Regeneron, Inc. (R), Regeneron, Inc. (F);
Laurens Bouckaert, Allegro (C), Allegro (I);
Nick Boucher, Vestrum Health (E);
Namrata Saroj, Allegro (C), Allegro (I), Apellis (C), Regeneron (C)